DREAMM-20

In this open-label dose-escalation study, 18 patients with ≥3 prior lines of therapy (94% triple-class exposed) were treated with belantamab monotherapy IV every 2 weeks at doses of 300 mg, 900 mg, or 2000 mg (n = 6 per cohort). The median age was 76 years (range, 42 to 86), and 2 patients had received prior BCMA-directed therapy.

The median duration of exposure was 63.5 days, and no dose-limiting toxicities or adverse reactions led to treatment discontinuation. The most common treatment-related adverse events were infusion reactions (22%) and hematologic events. The most common grade 3 or higher adverse events were neutrophil count decrease (22%) and anemia (17%).

The overall response rate (ORR) was 28%, including 2 very good partial responses and 3 partial responses. Disease was observed in another five patients (28%).